Effects of Erythropoietin on Depressive Symptoms and Neurocognitive Deficits in Depression and Bipolar Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Mood Disorders
Interventions
DRUG

Erythropoietin

40.000 IU/ml epoetin alfa is administered as intravenous infusions over 15 min weekly for 8 weeks.

Trial Locations (1)

2200

Copenhagen University Hospital, Rigshospitalet, Copenhagen

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

The Ministry of Science, Technology and Innovation, Denmark

OTHER_GOV

collaborator

Novo Nordisk A/S

INDUSTRY

collaborator

University of Oxford

OTHER

collaborator

Max-Planck-Institute of Experimental Medicine

OTHER

lead

Lars Vedel Kessing, professor, MD, DMSc.

OTHER

NCT00916552 - Effects of Erythropoietin on Depressive Symptoms and Neurocognitive Deficits in Depression and Bipolar Disorder | Biotech Hunter | Biotech Hunter